A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
Bristol-Myers Squibb
Nammi Therapeutics Inc
Jazz Pharmaceuticals
EMD Serono
SystImmune Inc.
GI Innovation, Inc.
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Genmab
Myeloid Therapeutics
Daiichi Sankyo
Avacta Life Sciences Ltd
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Innate Pharma
Dren Bio
Tanabe Pharma America, Inc.
Massive Bio, Inc.
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Incyte Corporation
Xencor, Inc.
Incyte Corporation
NextPoint Therapeutics, Inc.
OncoC4, Inc.
Monopar Therapeutics
Monopar Therapeutics
Klus Pharma Inc.
Cofactor Genomics, Inc.
Checkpoint Therapeutics, Inc.
RAPT Therapeutics, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Molecular Templates, Inc.
Salubris Biotherapeutics Inc
Pfizer
Xencor, Inc.
Pliant Therapeutics, Inc.
Sumitomo Pharma America, Inc.
NextCure, Inc.
Evopoint Biosciences Inc.
pharmaand GmbH
Atreca, Inc.
Fate Therapeutics